PA 2794

Drug Profile

PA 2794

Latest Information Update: 12 Oct 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chiron Corporation; Nektar Therapeutics
  • Developer Nektar Therapeutics
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Respiratory tract infections

Most Recent Events

  • 31 Dec 2003 Discontinued - Preclinical for Respiratory tract infections in USA (Inhalation)
  • 15 Jan 2003 Inhale Therapeutic Systems is now called Nektar Therapeutics
  • 19 Jul 2002 Preclinical trials in Respiratory tract infections in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top